Yamini Natarajan1, Donna L White2,3,4,5,6, Hashem B El-Serag2,3,4,5, David Ramsey3, Peter Richardson3, Jill Kuzniarek3, Richa Shukla2, Aylin Tansel2, Fasiha Kanwal2,3,4,5. 1. Section of Gastroenterology and Hepatology, Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, TX, USA. Yamini.Natarajan@va.gov. 2. Section of Gastroenterology and Hepatology, Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, TX, USA. 3. Clinical Epidemiology and Comparative Effectiveness Program, Section of Health Services Research (IQuESt), Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, TX, USA. 4. Texas Medical Center Digestive Disease Center, Houston, TX, USA. 5. Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, TX, USA. 6. Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA.
Abstract
BACKGROUND: Medical comorbidities and functional status limitations are determinants of mortality in many chronic diseases. The extent to which survival in the rapidly aging cohort of patients with HCV is affected by these competing causes of mortality remains unclear. AIM: We sought to determine the effect of medical/functional comorbidities on survival after adjusting for liver disease severity in a cohort of patients with HCV infection. METHODS: We prospectively recruited consecutive patients from an HCV clinic 2009-2014. We calculated an index of survival (Schonberg Index, SI) based on age, gender, medical comorbidities, and functional status variables. We defined cirrhosis with the FibroSure test (F3/4-F4). We used multivariable Cox modeling to assess association between functional/survival measure and survival after adjustment for severity of liver disease. RESULTS: The cohort consisted of 1052 HCV patients. The average age was 56.8 years; 36 % had cirrhosis. The mean SI was 8.2 (SD = 2.7). During a mean follow-up of 5610 person-years, 102 (9.7 %) patients died. In unadjusted analysis, higher baseline SI predicted mortality (HR 1.17; 95 % CI 1.09-1.25). SI similarly predicted mortality in cirrhotic patients (HR 1.23, 95 % CI 1.13-1.34) and non-cirrhotic patients (HR 1.21, 95 % CI 1.08-1.36). This did not change after adjusting for age, drug use, or coronary artery disease. DISCUSSION: Comorbidities and functional limitations predict higher mortality in patients with HCV; this relationship is independent of cirrhosis. Use of general prognostic indices may help identify HCV patients at high risk for mortality, which could further guide clinical care in a manner not achievable with assessment of liver disease alone.
BACKGROUND: Medical comorbidities and functional status limitations are determinants of mortality in many chronic diseases. The extent to which survival in the rapidly aging cohort of patients with HCV is affected by these competing causes of mortality remains unclear. AIM: We sought to determine the effect of medical/functional comorbidities on survival after adjusting for liver disease severity in a cohort of patients with HCV infection. METHODS: We prospectively recruited consecutive patients from an HCV clinic 2009-2014. We calculated an index of survival (Schonberg Index, SI) based on age, gender, medical comorbidities, and functional status variables. We defined cirrhosis with the FibroSure test (F3/4-F4). We used multivariable Cox modeling to assess association between functional/survival measure and survival after adjustment for severity of liver disease. RESULTS: The cohort consisted of 1052 HCV patients. The average age was 56.8 years; 36 % had cirrhosis. The mean SI was 8.2 (SD = 2.7). During a mean follow-up of 5610 person-years, 102 (9.7 %) patients died. In unadjusted analysis, higher baseline SI predicted mortality (HR 1.17; 95 % CI 1.09-1.25). SI similarly predicted mortality in cirrhoticpatients (HR 1.23, 95 % CI 1.13-1.34) and non-cirrhoticpatients (HR 1.21, 95 % CI 1.08-1.36). This did not change after adjusting for age, drug use, or coronary artery disease. DISCUSSION: Comorbidities and functional limitations predict higher mortality in patients with HCV; this relationship is independent of cirrhosis. Use of general prognostic indices may help identify HCV patients at high risk for mortality, which could further guide clinical care in a manner not achievable with assessment of liver disease alone.
Authors: M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis Journal: N Engl J Med Date: 1999-08-19 Impact factor: 91.245
Authors: D Saliba; M Elliott; L Z Rubenstein; D H Solomon; R T Young; C J Kamberg; C Roth; C H MacLean; P G Shekelle; E M Sloss; N S Wenger Journal: J Am Geriatr Soc Date: 2001-12 Impact factor: 5.562
Authors: Michael W Drazer; Sandip M Prasad; Dezheng Huo; Mara A Schonberg; William Dale; Russell Z Szmulewitz; Scott E Eggener Journal: Cancer Date: 2014-02-12 Impact factor: 6.860
Authors: Kathleen F Kerr; Zheyu Wang; Holly Janes; Robyn L McClelland; Bruce M Psaty; Margaret S Pepe Journal: Epidemiology Date: 2014-01 Impact factor: 4.822
Authors: Marwan Ghabril; Jiezhun Gu; Lindsay Yoder; Laura Corbito; Amit Ringel; Christian D Beyer; Raj Vuppalanchi; Huiman Barnhart; Paul H Hayashi; Naga Chalasani Journal: Gastroenterology Date: 2019-07-11 Impact factor: 22.682